lp-108
Small moleculeexperimental
Clinical trial activity
3 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2019 (NCT04139434)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Apoptosis regulator Bcl-2INHIBITOR
BCL2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05641259 | Phase 1 | Dec 10, 2022 | China Medical University, Chongqing Medical University, Guangzhou Lupeng Pharmaceutical Company LTD., Huazhong University of Science and Technology, Nanchang University, Soochow University |
| NCT04356846 | Phase 1 | May 1, 2020 | Nanjing Medical University, Newave Pharmaceutical Inc |
| NCT04139434 | Phase 1 | Dec 31, 2019 | Newave Pharmaceutical Inc |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Newave Pharmaceutical Inc | For profit | 2 | 1 | 1 | 2019 |
| China Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Chongqing Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | For profit | 1 | 1 | 1 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Nanchang University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Nanjing Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Soochow University | Academic/Hospital | 1 | 0 | 1 | 2022 |
8 organizations
Page 1 / 1